Malik, Raleigh

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

Frias, J. P., Bonora, E., Nevarez Ruiz, L., Li, Y. G., Yu, Z., Milicevic, Z., Malik, R., Bethel, M. A., & Cox, D. A. (2021) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 199

Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD ‐11

Bonora, E., Frias, J. P., Tinahones, F. J., Van, J., Malik, R. E., Yu, Z., Mody, R., Bethel, A., Kwan, A. Y. M., & Cox, D. A. (2021) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 67

Dulaglutide and Kidney Function–Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis

Botros, F. T., Gerstein, H. C., Malik, R., Nicolay, C., Hoover, A., Turfanda, I., Colhoun, H. M., & Shaw, J. E. (2023) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 42

Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison

le Roux, C. W., Hankosky, E. R., Wang, D., Malik, R., Yu, M., Hickey, A., Kan, H., Bunck, M. C., Stefanski, A., Garcia‐Perez, L., et al. (2023) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 36

Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice

Mody, R., Manjelievskaia, J., Marchlewicz, E. H., Malik, R. E., Zimmerman, N. M., Irwin, D. E., & Yu, M. (2022) · Clinical Therapeutics

Medication Adherence and ComplianceDiabetes Treatment and Management

Cited by 22